Recombinant Human Fibroblast Growth Factor 13 (FGF13) Protein (His)

Beta LifeScience SKU/CAT #: BLC-08921P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Fibroblast Growth Factor 13 (FGF13) Protein (His)

Beta LifeScience SKU/CAT #: BLC-08921P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Fibroblast Growth Factor 13 (FGF13) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb Q92913
Target Symbol FGF13
Synonyms FGF 13; FGF 2; FGF-13; FGF13; FGF13_HUMAN; FGF2; FHF 2; FHF-2; FHF2; Fibroblast growth factor 13; Fibroblast growth factor homologous factor 2; OTTHUMP00000024143; OTTHUMP00000024144
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His
Target Protein Sequence MAAAIASSLIRQKRQAREREKSNACKCVSSPSKGKTSCDKNKLNVFSRVKLFGSKKRRRRRPEPQLKGIVTKLYSRQGYHLQLQADGTIDGTKDEDSTYTLFNLIPVGLRVVAIQGVQTKLYLAMNSEGYLYTSELFTPECKFKESVFENYYVTYSSMIYRQQQSGRGWYLGLNKEGEIMKGNHVKKNKPAAHFLPKPLKVAMYKEPSLHDLTEFSRSGSGTPTKSRSVSGVLNGGKSMSHNEST
Expression Range 1-245aa
Protein Length Full Length
Mol. Weight 31.6kDa
Research Area Signal Transduction
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Microtubule-binding protein which directly binds tubulin and is involved in both polymerization and stabilization of microtubules. Through its action on microtubules, may participate in the refinement of axons by negatively regulating axonal and leading processes branching. Plays a crucial role in neuron polarization and migration in the cerebral cortex and the hippocampus. May regulate voltage-gated sodium channels transport and function. May also play a role in MAPK signaling. Required for the development of axonal initial segment-targeting inhibitory GABAergic synapses made by chandelier neurons.
Subcellular Location Cell projection, filopodium. Cell projection, growth cone. Cell projection, dendrite. Nucleus. Cytoplasm.; [Isoform 1]: Nucleus, nucleolus.; [Isoform 2]: Cytoplasm. Nucleus.
Protein Families Heparin-binding growth factors family
Database References
Tissue Specificity Ubiquitously expressed. Predominantly expressed in the nervous system.

Gene Functions References

  1. The present study reported the presence of FGF13 in the follicular fluid of women undergoing IVF/ICSI. Moreover, the relationships between FF-FGF13 and FF-TT, ovarian morphology and oocyte developmental competence imply that FF-FGF13 might be involved in the pathophysiological process of polycystic ovary syndrome. PMID: 30257687
  2. Autism-related protein MeCP2 regulates FGF13 expression and emotional behaviors PMID: 27916441
  3. FGF13 was downregulated in human placentae with early-onset preeclampsia. FGF13 played an important role in maintaining placental trophoblast permeability via the modulation of E-cadherin. PMID: 29405966
  4. We propose that, in cells in which activated oncogenes drive excessive protein synthesis, FGF13 may favor survival by maintaining translation rates at a level compatible with the protein quality-control capacity of the cell. Thus, FGF13 may serve as an enabler, allowing cancer cells to evade proteostasis stress triggered by oncogene activation. PMID: 27994142
  5. Study screened the coding and splice site regions of the FGF13 gene in a sample of 45 unrelated probands where genetic epilepsy with febrile seizures plus segregated in an X-linked pattern; subsequently identified a de novo FGF13 missense variant in an additional patient with febrile seizures and facial edema. Results suggest that FGF13 is not a common cause of genetic epilepsy with febrile seizures plus. PMID: 27810516
  6. identified two novel native phosphorylation sites in the C terminus of NaV1.5 that impair FGF13-dependent regulation of channel inactivation and may contribute to CaMKIIdeltac-dependent arrhythmogenic disorders in failing hearts. PMID: 28882890
  7. These data showed the diversity of the roles of the FGF13 N-termini in NaV1.5 channel modulation and suggested the importance of isoform-specific regulation PMID: 27246624
  8. the FGF13/Nav1.7 complex is essential for sustaining the transmission of noxious heat signals PMID: 28162808
  9. for PCa patients after RP, FGF13 serves as a potential novel prognostic marker that improves prediction of BCR-free survival, in particular if combined with other clinical parameters. PMID: 26891277
  10. The findings of this study reveal a novel cause of this syndrome and underscore the powerful role of FGF13 in control of neuronal excitability. PMID: 26063919
  11. X-chromosome deletions may be a cause of WS with larger deletions being lethal to males and that FGF13 mutations may be a cause of Wildervanck Syndrome (WS). PMID: 23373430
  12. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells PMID: 24113164
  13. FGF13 has a role in hair follicle growth and in the hair cycle as shown in a family with X-linked congenital generalized hypertrichosis PMID: 23603273
  14. interactions with perlecans PMID: 11847221
  15. identification of a domain controlling angiogenic properties PMID: 12496262
  16. FHF2B is an interacting partner of Na(v)1.6. The preferential expression of FHF2B in sensory neurons may provide a basis for physiological differences in sodium currents that have been reported at the nodes of Ranvier in sensory versus motor axons. PMID: 15282281

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

More from Cytokines
Recently viewed